Ariceum appoints CFO

Ariceum Therapeutics GmbH, a biotech developing radiopharmaceutical products for certain hard-to-treat cancers, has appointed David Schilansky as chief financial officer, succeeding Rainer Sturm. He brings a strong track record in company scale-up and fundraising, including on Nasdaq, having led two IPOs on Euronext and Nasdaq for DBV Technologies where he co-headed the French biopharma company from 2011 to 2020. In 2020, Mr Schilansky co-founded Home Biosciences, a biotech venture builder, and built three start-ups. Ariceum’s lead radiopharmaceutical candidate, satoreotide, is in Phase 1b clinical trials. The Germany-based company was launched in 2021 and acquired the rights to satoreotide from Ipsen, which remains a shareholder.

Ariceum announced the appointment on 10 January 2025.